Models
1
Overview
Stereotaxis is an American medical device company based in St. Louis, Missouri, developing magnetic navigation technology for robotic cardiology procedures. Its Genesis RMN system uses robotically controlled magnets to guide flexible catheters with magnetic tips during cardiac ablation procedures, and received FDA clearance and NMPA approval in China.
Verified record
- Verified deployments
- None on file
- Active incidents
- None on file
DEPLOY Intelligence
Market intelligence for physical AI
Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.
Key facts
Product
Gating events
Stock listing
Installed base
CEO
Regulatory
Listed on
Data & sources
Press releases
3
3 sources backing this record.View all →
Models (1)
View all models →Explainers
Plain-language answers to the questions people ask about Stereotaxis, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.
- What is a surgical robot?
A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.
Current leadership (1)
- David Fischel Chairman & CEOreported, not verified
Safety record
No incidents on record for Stereotaxis.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Full safety record: incidents, sourcing, and exposure data →
Recent coverage
Stereotaxis in third-party press
Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
Financial state
- Reporting basis
- aggregator_estimate
- Lifecycle stage
- mature
- Counterparty risk class
- low
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Regulatory filings (1)
- fda_510kfda 510k · us_fdacleared2024-01-01
Linked models: Genesis RMN / GenesisX
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 5, 2026
Stereotaxis Genesis robotic magnetic navigation
- Record createdJun 3, 2026
Added to the verified registry
- Deployment verifiedVerifiedJan 1, 2019
Genesis RMN / GenesisX at United States
Sources (3)
Common questions
- What is Stereotaxis?
- Stereotaxis is an American medical device company based in St. Louis, Missouri, developing magnetic navigation technology for robotic cardiology procedures. Its Genesis RMN system uses robotically controlled magnets to guide flexible catheters with magnetic tips during cardiac ablation procedures, and received FDA clearance and NMPA approval in China.
- What does Stereotaxis make?
- Stereotaxis has 1 robot model on the DEPLOY registry: Genesis RMN / GenesisX (Stereotaxis builds both physical robots and the AI that runs them).
- Is Stereotaxis publicly traded?
- Yes. Stereotaxis is publicly traded on public markets, per the DEPLOY registry.
- Who competes with Stereotaxis?
- On the DEPLOY registry, peer companies to Stereotaxis building in the same form factors include Johnson & Johnson, Intuitive Surgical, LEM Surgical, MicroPort MedBot.
- Who is the CEO of Stereotaxis?
- David Fischel is the ceo of Stereotaxis, per the DEPLOY registry.
- How can I invest in Stereotaxis?
- Stereotaxis is publicly traded (public markets), so its shares can be bought through any broker.
- Where is Stereotaxis headquartered?
- Stereotaxis is headquartered in St. Louis, MO, USA.
- Who owns Stereotaxis?
- Stereotaxis is publicly held by its shareholders.
- Where does Stereotaxis operate robots?
- Stereotaxis is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is Stereotaxis a top robotics company?
- On DEPLOY's intelligence score, which blends verified deployments, funding, hiring, media, safety, and IP signals, Stereotaxis ranks in roughly the top 57% of companies tracked by the registry.
- When was Stereotaxis founded?
- Stereotaxis was founded in 1990.
- Is Stereotaxis safe?
- Stereotaxis has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 3 sources (3 primary) · last reviewed 2026-07-03
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-03
Sources by quality tier
- 3
- primary-company-ir
- Company IR disclosure
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Stereotaxis.Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
In the press
Recent coverage mentioning Stereotaxis from third-party publications. Automatically surfaced; not part of the verified registry record.
Stereotaxis Next-Gen Endovascular Surgical Robot Receives 510k Clearance from FDA
Stereotaxis received FDA 510(k) clearance for its next-generation endovascular surgical robot, advancing minimally invasive cardiac procedures.
Stereotaxis Expands Endovascular Reach with 5M Robocath Acquisition
Stereotaxis acquired Robocath for 5M to expand its endovascular robotic surgery reach.
Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis
Stereotaxis received FDA clearance for the Genesis RMN system, a leap forward in Robotic Magnetic Navigation technology for cardiac procedures.
Machine-readable surfaces
- Markdown mirror: /companies/stereotaxis.md
- RSS feed: /companies/stereotaxis/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/e401d2c7-b035-4dea-9b60-ae0d2bb9b99b
- Revision history: /companies/stereotaxis/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Johnson & Johnson3 models
- Intuitive Surgical2 models
- LEM Surgical2 models
- MicroPort MedBot2 models
- Neocis2 models
- Stryker2 models
Video
Robotic Magnetic Navigation (RMN) introduces the benefits of highly sophisticated robotics technology to allow for safe and effective cardiac ablation procedure
Hear from users of the latest generation of robotic catheter navigation technology, the Stereotaxis Genesis Robotic Magnetic Navigation system. In this summary
Stereotaxis presents the latest in Robotic Magnetic Navigation (RMN), the Genesis RMN system. Genesis is a leap forward in robotic technology and represents th
Silent video demonstrating the movement of the Stereotaxis robotic navigation system around the patient bedside.
Demonstration of the magnetically guided catheter navigating through several turns while maintaining maneuverability. Learn more about Stereotaxis Robotic Magne
Animation demonstration of how Stereotaxis robotically navigates the human body with the use of magnetic technology.
#STXS, $STXS As part of my research in evaluating both stocks I own and and stocks I am considering taking a position in, I immerse myself in technical analysi
David Fischel, Chairman & CEO of Stereotaxis, breaks down the company’s bold R&D strategy and the three major innovations driving the future of robotic surgery.
They’re letting robots put catheters inside people?! Today, we're talking to David Fischel, CEO at Stereotaxis. We discuss the revolutionary impact of robotic s
1. Nvidia partners with Stereotaxis to integrate AI into endovascular surgical robotics. 2. The GenesisX surgical robot system gains new capabilities with Nvidi
In this episode, we’re joined by Stereotaxis CEO David Fischel, who shares the remarkable story of his company’s journey. Discover how Stereotaxis is revolution
Get it? Attractive? Magnets. Yeh, we’ll, we’re tired from putting this monster podcast episode together but it’s so, so good. You’ll hear from David Fischel,
Today's SSI MedTech "In the News Development" is brought to you by SSI President Darwin Shurig. Darwin discusses Stereotaxis and their new Genesis Robotic Magne
Reality vs attention
Stereotaxis draws attention at the 54th percentile but verifies reality at the 21st percentile among surgical robots. Hype Gap +32.8, 7th widest among surgical robots.
6-month trend
Analysis
Clean safety record across 1 verified deployment. Deployment footprint remains limited relative to category peers.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 18, 2026